deltatrials
Completed PHASE1 INTERVENTIONAL 1-arm NCT03032107

A Study Of Pembrolizumab In Combination With Trastuzumab-DM1

A Phase 1b Study Of Pembrolizumab In Combination With Trastuzumab-DM1 In Metastatic HER2-Positive Breast Cancer

Sponsor: Dana-Farber Cancer Institute

Conditions Breast Cancer
Interventions Pembrolizumab T-DM1
Updated 15 times since 2017 Last updated: Jan 14, 2025 Started: Feb 17, 2017 Primary completion: Oct 29, 2020 Completion: Dec 5, 2024
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Breast Cancer, this trial is completed. The trial is conducted by Dana-Farber Cancer Institute and has accumulated 15 data snapshots since 2017. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Feb 2017 – ~Mar 2017 · 28 days · monthly snapshot~Mar 2017 – ~Apr 2017 · 31 days · monthly snapshot~Apr 2017 – ~Jun 2018 · 14 months · monthly snapshot~Jun 2018 – ~Jun 2019 · 12 months · monthly snapshot~Jun 2019 – ~Sep 2020 · 15 months · monthly snapshot~Sep 2020 – ~Jan 2021 · 4 months · monthly snapshot~Jan 2021 – ~Sep 2021 · 8 months · monthly snapshot~Sep 2021 – ~Jun 2022 · 9 months · monthly snapshot~Jun 2022 – ~Sep 2022 · 3 months · monthly snapshot~Sep 2022 – ~Jul 2024 · 22 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Dec 2024 · 3 months · monthly snapshot~Dec 2024 – ~Jan 2025 · 31 days · monthly snapshot~Jan 2025 – ~Feb 2025 · 31 days · monthly snapshot~Feb 2025 – present · 17 months · monthly snapshot

Change History

15 versions recorded

  1. Feb 2025 — Present [monthly]

    Completed PHASE1

    Status: Active Not Recruiting → Completed

  2. Jan 2025 — Feb 2025 [monthly]

    Active Not Recruiting PHASE1

  3. Dec 2024 — Jan 2025 [monthly]

    Active Not Recruiting PHASE1

  4. Sep 2024 — Dec 2024 [monthly]

    Active Not Recruiting PHASE1

  5. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE1

▶ Show 10 earlier versions

  1. Sep 2022 — Jul 2024 [monthly]

    Active Not Recruiting PHASE1

  2. Jun 2022 — Sep 2022 [monthly]

    Active Not Recruiting PHASE1

  3. Sep 2021 — Jun 2022 [monthly]

    Active Not Recruiting PHASE1

  4. Jan 2021 — Sep 2021 [monthly]

    Active Not Recruiting PHASE1

  5. Sep 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE1

    Status: Recruiting → Active Not Recruiting

  6. Jun 2019 — Sep 2020 [monthly]

    Recruiting PHASE1

  7. Jun 2018 — Jun 2019 [monthly]

    Recruiting PHASE1

  8. Apr 2017 — Jun 2018 [monthly]

    Recruiting PHASE1

  9. Mar 2017 — Apr 2017 [monthly]

    Recruiting PHASE1

    Status: Not Yet Recruiting → Recruiting

  10. Feb 2017 — Mar 2017 [monthly]

    Not Yet Recruiting PHASE1

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Dana-Farber Cancer Institute
  • Merck Sharp & Dohme LLC
Data source: Dana-Farber Cancer Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations